Skip to main content
Healthcare

STAT+: Vertex kidney disease drug scrutinized for infection risk

STAT+: Vertex kidney disease drug scrutinized for infection risk

Feed excerpt — reported by STAT News

Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.